Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) shares were down 4.22% on Tuesday to $0.893 and recovered 4.10% in after-hours trading. Share prices were trading in a 52-week range of $0.26 to $2.43. The company has a market cap of $147.97 million at 155.75 million shares outstanding.
Navidea Biopharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. This Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.
In a press release yesterday, Navidea Biopharmaceuticals Inc announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and Chief Executive Officer.
Dr. Goldberg is a visionary leader with a deep knowledge and appreciation for the potential of Navidea’s macrophage targeting technology platform and its wide range of diagnostic and therapeutic applications. At this important transition point for the Company, we will benefit greatly from his expertise as we drive the development of our Manocept™ clinical immunodiagnostic and immunotherapeutic programs to deliver targeted products to improve patient outcomes,” said Dr. Rowinsky, Chairman of Navidea’s Compensation, Nominating and Governance committee and newly appointed Chairman.
Goldberg also mentioned that he looks forward to spearheading the growth of both Navidea and Macrophage Therapeutics as they work on their mission to not only diagnose but treat disease.
The combination of exceptional technology, a strong leadership team as well as our expectation of improved financial stability will allow us to effectively execute on our strategy to more rapidly advance on numerous development programs with our ground-breaking proprietary technology for multiple high value indications,” Goldberg explained.
Prior to this position, Golberg served as the Chairman of the Board and Chief Executive Officer of Emisphere Technologies, which is the pioneer in the development of oral delivery technologies for macromolecules.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
